EZN-2968: Phase I data

Data from 26 evaluable patients in an ongoing, open-label, dose-escalation, U.S. Phase I trial showed that 0.5-6.2 mg/kg/day IV EZN-2968 resulted in 4 cases of stable disease. EZN-2968 was well tolera...